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Introduction
According to a previous study (Soars et al., 2002) , 45, 3, and 45 mg/g tissue were used as the contents of the microsomal protein in liver, intestine, and kidney, respectively. Twenty, 30, and 4.4 g/kg body weight were used as the weights of liver, intestine, and kidney, respectively.
Immunoblot analysis of recombinant human UGT1A isoforms. SDS-polyacrylamide gel
electrophoresis and immunoblot analysis of recombinant UGT1A isoforms were performed according to Laemmli (1970) . The microsomes from baculovirus-infected insect cells (0.5 µg)
were separated on 10% polyacrylamide gel and transferred electrophoretically to a PVDF membrane Immobilon-P (Millipore, Bedford, MA). Rabbit anti-human UGT1A polyclonal antibodies (BD Gentest) react with all human UGT1A isoforms, since the antibodies recognize the conserved C-terminal region of UGT1A isoforms (Malfatti and Felton, 2004) .
Biotinylated anti-rabbit IgG and VECTASTAIN ABC kit (Vector Laboratories, Burlingame, CA) were used for diaminobenzidine staining. The densities of the bands were determined using an ImageQuant (GE Healthcare Bio-Science, Piscataway, NJ). For each isoform, the densities of multiple bands, possibly owing to variability in the glycosylation (Malfatti and Felton, 2004) , were summed for the quantification. The expression level of UGT1A was defined based on a standard curve using the recombinant UGT1A1 (1 unit per 1 mg protein).
This article has not been copyedited and formatted. The final version may differ from this version. et al., 2000) . Imipramine is a substrate of UGT1A3 and UGT1A4 (Green and Tephly, 1998) . Emodin is a substrate of UGT1A1, UGT1A3, UGT1A8 and UGT1A9 (King et al., 2000) . Propofol is a substrate of UGT1A8 and UGT1A9 (King et al., 2000) . Troglitazone is a substrate of UGT1A1, UGT1A8, and UGT1A10 (Watanabe et al., 2002) . Bilirubin was dissolved in 0.1 M sodium hydroxide. Imipramine hydrochloride was dissolved in water.
Emodin and troglitazone were dissolved in dimethyl sulfoxide. Propofol was dissolved in methanol. These compounds were added to the incubation mixtures described above to investigate their inhibitory effects on the thyroxine glucuronosyltransferase activities in human liver, jejunum, and kidney microsomes or recombinant UGTs. The final concentration of the organic solvents in the incubation mixture was < 2% (v/v). The substrate concentration was 20 µM.
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Results
Thyroxine glucuronosyltransferase activities in human liver, jejunum, or kidney microsomes. The formation of thyroxine glucuronide increased in microsomal protein concentration-and time-dependent manners. The formations were linear at least for 0.5 mg/ml microsomal protein and 120 min incubation (data not shown). Unless specified, the typical incubation mixture containing 0.4 mg/ml microsomal protein was incubated at 37°C for 90 min. The kinetics of thyroxine glucuronosyltransferase activities in human liver, jejunum, and kidney microsomes were fitted to the Michaelis-Menten equation (Fig. 2A) . The
Eadie-Hofstee plots were monophasic (Fig. 2B) Thyroxine glucuronosyltransferase activities by recombinant UGT isoforms. Eleven recombinant UGT isoforms expressed in baculovirus-infected insect cells were used to determine their thyroxine glucuronosyltransferase activities. As shown in Fig. 3A , UGT1A8
exhibited the highest thyroxine glucuronosyltransferase activity (87 pmol/min/mg), followed by UGT1A1 (26 pmol/min/mg), UGT1A10 (20 pmol/min/mg), UGT1A3 (18 pmol/min/mg), UGT1A9 (5 pmol/min/mg), and UGT1A7 (5 pmol/min/mg). To quantify the expression level of UGT1A in each expression system, immunoblot analysis was performed (Fig. 3B ). In accordance with previous studies (Malfatti and Felton, 2004; Fujiwara et al., 2007) , the recombinant UGT1A isoforms showed multiple bands, possibly owing to variability in the glycosylation. Based on a UGT1A1 level of 1.00 unit/mg, the expression levels of the other This article has not been copyedited and formatted. The final version may differ from this version. 3C ), UGT1A8 (108.7 pmol/min/unit) and UGT1A3 (91.6 pmol/min/unit) exhibited the highest thyroxine glucuronosyltransferase activities, followed by UGT1A10 (47.3 pmol/min/unit) and UGT1A1 (26.0 pmol/min/unit). The activities by UGT1A7 (7.6 pmol/min/unit) and UGT1A9 (7.1 pmol/min/unit) were low.
Kinetics of thyroxine glucuronosyltransferase activities by recombinant UGT1A
isoforms. For six UGT isoforms showing thyroxine glucuronosyltransferase activity, kinetic analyses were performed. The kinetics of thyroxine glucuronosyltransferase activities by recombinant UGT1A1, UGT1A7, and UGT1A9 fitted to the Michaelis-Menten kinetics ( Fig.   4A ). The activities by recombinant UGT1A3, UGT1A8, and UGT1A10 fitted to the substrate inhibition kinetics (Fig. 4B ). The apparent Km and corrected Vmax values are summarized in Table 2 . The Km values varied from 24.1 µM to 104.9 µM. UGT1A8 (6.6 µl/min/unit) exhibited the highest clearance, followed by UGT1A3 (6.2 µl/min/unit) and by UGT1A10 O-glucuronidation catalyzed by UGT1A8 and UGT1A9, or morphine 3-O-glucuronidation catalyzed by UGT2B7 (Table 3) . Since UGT1A8 is not expressed in human liver, the estradiol 3-O-and propofol O-glucuronosyltransferase activities represented are the UGT1A1 and UGT1A9 activities, respectively. The thyroxine glucuronosyltransferase activities in 12 human liver microsomes were significantly correlated with bilirubin (r = 0.855, p < 0.001), estradiol (r = 0.827, p < 0.0001), and serotonin (r = 0.522, p < 0.05) glucuronidations.
Inhibitory effects of typical substrates for UGT isoforms on thyroxine glucuronosyltransferase activities in human liver, jejunum, and kidney microsomes or recombinant UGTs. The inhibitory effects of bilirubin, imipramine, emodin, propofol and troglitazone on the thyroxine glucuronosyltransferase activity were investigated. These inhibitors were used at effective concentrations according to the previous studies (Watanabe et al., 2002; Kuehl et al., 2005; Yamanaka et al., 2005) . The thyroxine glucuronosyltransferase activity in human liver microsomes was strongly inhibited by bilirubin (29% of control) and emodin (15% of control), and was moderately inhibited by troglitazone (51% of control), but was activated by propofol (121% of control) (Fig. 5A ). The thyroxine glucuronosyltransferase activity in human jejunum microsomes was strongly inhibited by emodin (45% of control), and was moderately inhibited by bilirubin (68% of control). The thyroxine glucuronosyltransferase activity in human kidney microsomes was strongly inhibited by troglitazone (46% of control), and was moderately inhibited by emodin (55% of control).
Thus, the effects of these compounds on the activity were different between the tissues. The inhibitory effects on thyroxine glucuronidation were also investigated for recombinant UGT1A isoforms (Fig. 5B) . Bilirubin strongly inhibited the activity by UGT1A1 (16% of control), and moderately inhibited the activities by UGT1A7 (68% of control). Imipramine moderately inhibited the activity by UGT1A3 (68% of control) and UGT1A10 (64% of control 
Discussion
In this study, we extensively investigated the thyroxine glucuronidation in human liver, jejunum, and kidney microsomes and recombinant UGTs. The tissue clearances in liver, intestine, and kidney were estimated to be 1440, 702, and 79 µl/min/kg of body weight, respectively. Although the UGT activities are not the same in the region of intestine (Strassburg et al., 2000) , it was first demonstrated that intestine exhibited approximately one half the clearance of liver for thyroxine glucuronidation. The glucuronidation in intestine may affect the enterohepatic circulation of thyroxine. In kidney, thyroxine is highly converted to T3 with Km = 3.0 µM, Vmax = 26.1 pmol/min/mg, and Vmax/Km = 8.7 µl/min/mg (Boye, 1986) . In addition to the outer ring deiodination, this study demonstrated that thyroxine is glucuronidated in kidney.
This is the first study demonstrating that human UGT1A8, UGT1A10, and UGT1A3
have high, and UGT1A1 has moderate catalytic activity toward thyroxine glucuronidation.
Since UGT isoforms are differently expressed in human liver, jejunum, and kidney, it was conceivable that UGT isoform(s) responsible for the thyroxine glucuronidation might be different between these tissues. If the absolute protein levels of each UGT isoform in human tissues are available, quantitative estimation of the contribution of each isoform to the concerned activity can be accomplished like cytochrome P450 (Becquemont et al., 1998) .
Unfortunately, for UGT, a methodology of quantification is lacking. In addition, specific antibodies against each UGT1A isoform are limited. In the present study, we qualitatively identified the UGT isoforms that are responsible for the thyroxine glucuronidation in human tissues by kinetic, correlation, and inhibition analyses as well as tissue distribution of each UGT isoform.
The Eadie-Hofstee plots of thyroxine glucuronosyltransferase activities in human liver, jejunum, and kidney microsomes were monophasic, suggesting that one or more UGT isoform(s) would be involved in the activities. In human liver microsomes, the apparent Km value was similar to that of recombinant UGT1A1. The activity in a panel of human liver (Table 3) , and imipramine did not inhibit the thyroxine glucuronosyltransferase activity (Fig. 5) although it inhibited the chenodeoxycholic acid 24-O-glucuronosyltransferase activity by 48% of control (data not shown).
In human jejunum microsomes, the apparent Km value was similar to that of recombinant UGT1A8. The thyroxine glucuronidation in human jejunum microsomes was inhibited by emodin, and was moderately inhibited by bilirubin. These results suggested that the thyroxine glucuronidation in human jejunum microsomes might be catalyzed mainly by UGT1A8 and UGT1A10, and to a minor extent by UGT1A1. In human kidney microsomes, the apparent Km value was similar to that of recombinant UGT1A7. The thyroxine glucuronidation in human kidney microsomes was inhibited by troglitazone and emodin. It was suggested that the thyroxine glucuronidation in human kidney microsomes might be catalyzed by UGT1A7, UGT1A9, and UGT1A10. In summary, the contribution of each UGT1A isoform would vary between human tissues, depending on the relative abundance of each isoform.
In conclusion, we characterized the thyroxine glucuronidation in human liver, intestine, and kidney microsomes, and found that UGT1A1 in the liver, UGT1A8 and UGT1A10 in the intestine, and UGT1A7, UGT1A9, and UGT1A10 in the kidney mainly contribute to the activity. The change of activities of these UGTs via inhibition and induction by administered isoforms (0.5 µg) was performed using rabbit anti-human UGT1A antibodies. Control represents the UGT control Supersomes (0.5 µg). The expression levels were defined, assuming that UGT1A1 was 1.00 unit/mg. ND: not detected. 
